![](https://scdn.x-mol.com/css/images/icon-new-link.png)
样式: 排序: IF: - GO 导出 标记为已读
-
Diagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-13
Zhenyu Huo, Feifei Chong, Na Li, Siyu Luo, Liangyu Yin, Jie Liu, Mengyuan Zhang, Jing Guo, Yang Fan, Ling Zhang, Xin Lin, Hongmei Zhang, Muli Shi, Xiumei He, Zongliang Lu, Ning Tong, Wei Li, Jiuwei Cui, Zengqing Guo, Qinghua Yao, Fuxiang Zhou, Ming Liu, Zhikang Chen, Huiqing Yu, Minghua Cong, Tao Li, Zengning Li, Pingping Jia, Min Weng, Chunhua Song, Hanping Shi, Hongxia XuTo explore the association between cachexia, as defined by different diagnostic criteria, and the risk of mortality in individuals with cancer. We also examined which diagnostic criteria are more feasible and appropriate for cancer-associated cachexia in clinical practice.
-
Association Analysis of the Circulating Proteome With Sarcopenia-Related Traits Reveals Potential Drug Targets for Sarcopenia J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-13
Simin Wen, Siqi Xu, Xizeng Zong, Shifeng Wen, Wende Xiao, Weipeng Zheng, Han Cen, Zhaohua Zhu, Jingyu Xie, Yan Zhang, Changhai Ding, Guangfeng RuanSarcopenia severely affects the physical health of the elderly. Currently, there is no specific drug available for sarcopenia. This study aims to identify pathogenic proteins and druggable targets for sarcopenia through Mendelian randomization (MR)–based analytical framework.
-
Association of Cumulative Exposure to Metabolic Score for Visceral Fat With the Risk of Cardiovascular Disease and All‐Cause Mortality: A Prospective Cohort Study J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-12
Qian Liu, Haozhe Cui, Fei Si, Yuntao Wu, Jing YuBackgroundPrevious studies have demonstrated that metabolic score for visceral fat (METS‐VF), a novel surrogate indicator assessing visceral fat, was associated with the risk of hypertension, diabetes mellitus, cardiovascular disease (CVD) and mortality, predicting the risks based on a single METS‐VF measurement can increase limitations of the study. Few studies have investigated the association between
-
Neuroimaging Findings in Nondemented Frail Individuals: A Systematic Review J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-12
Hamid Harandi, Soheil Mohammadi, Ali Jahanshahi, Mahsa Dolatshahi, Sogol Alikarami, Rasa Zafari, Cyrus A. RajiBackgroundFrailty is a chronic condition characterised by the progressive decline of multiple physiological functions. There is a critical need to investigate neuroimaging findings in nondemented frail individuals to better understand the underlying mechanisms and implications of frailty on brain health. This paper is aimed at reviewing neuroimaging studies assessing brain changes in nondemented frail
-
Circulating Extracellular Vesicles in Alcoholic Liver Disease Affect Skeletal Muscle Homeostasis and Differentiation J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-11
Laura Barberi, Cristiana Porcu, Caterina Boccia, Marianna Cosentino, Carmine Nicoletti, Barbara Peruzzi, Francesca Iosi, Flavia Forconi, Giulia Bagnato, Gabriella Dobrowolny, Simone Di Cola, Lucia Lapenna, Gianluca Cera, Manuela Merli, Antonio MusaròBackgroundThe mechanisms underlying muscle alteration associated to alcoholic liver disease (ALD) are not fully understood and the physiopathologic mediators of the liver–muscle interplay remains elusive. We investigated the role of circulating extracellular vesicles (EVs) in ALD as potential mediators of muscle atrophy.MethodsWe established a mouse model of sarcopenia associated to ALD, by feeding
-
Long‐Term Impact of Physical Activity on Mortality in Adults With Multimorbidity: A 12‐Year Cohort Longitudinal Study From the Survey on Health, Ageing and Retirement in Europe J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-06
Nicola Veronese, Francesco Saverio Ragusa, André Hajek, Brendon Stubbs, Lee Smith, Mario Barbagallo, Ligia Juliana Dominguez, Luigi Fontana, Pinar Soysal, Shaun Sabico, Nasser M. Al‐DaghriBackgroundWhile physical activity (PA) is known to reduce mortality in the general population, this relationship in individuals with multimorbidity (≥ 2 chronic conditions) is unclear. This longitudinal study aimed to investigate whether there is a long‐term association between PA levels and mortality rates over a 12‐year period in adults with multimorbidity.MethodsData were obtained from eight waves
-
Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-06
Xiaofang Li, Jintao Xu, Shanshan Yao, Ning Zhang, Bao‐Ting Zhang, Zong‐Kang ZhangThe skeletal muscle is one of the largest organs in the body and is responsible for the mechanical activity required for posture, movement and breathing. The effects of current pharmaceutical therapies for skeletal muscle diseases are far from satisfactory; approximately 24% of Duchenne muscular dystrophy (DMD) trials have been terminated because of unsatisfactory outcomes. The lack of a skeletal muscle‐targeting
-
Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-06
Meiqiu Wang, Lianghui You, Xu He, Yingchao Peng, Ren Wang, Zhiqiang Zhang, Jiaping Shu, Pei Zhang, Xiaoyi Sun, LiLi Jia, Zhengkun Xia, Chenbo Ji, Chunlin GaoBackgroundThe presence of sarcopenia in patients with chronic kidney disease (CKD) is associated with poor prognosis. The mechanism underlying CKD‐induced muscle wasting has not yet been fully explored. This study investigates the influence of renal secretions on muscles using multiomics sequencing.MethodsThe kidney transcriptome analysis by RNA‐seq and protein profiling by tandem mass tag (TMT), serum
-
Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-04
Andrew I. Mikhail, Sean Y. Ng, Donald Xhuti, Magda A. Lesinski, Jennifer Chhor, Marc‐Olivier Deguise, Yves De Repentigny, Joshua P. Nederveen, Rashmi Kothary, Mark A. Tarnopolsky, Vladimir LjubicicBackgroundSpinal muscular atrophy (SMA) is a health‐ and life‐limiting neuromuscular disorder. Although varying degrees of mitochondrial abnormalities have been documented in SMA skeletal muscle, the influence of disease progression on pathways that govern organelle turnover and dynamics are poorly understood. Thus, the purpose of this study was to investigate skeletal muscle mitochondria during SMA
-
Nicotinamide Phosphoribosyltransferase Acetylation Mediating Muscle Dysfunction Contributes to Sleep Apnoea in Obesity J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-04
Liu Zhang, Ya Ru Yan, Shi Qi Li, Ying Ni Lin, Yi Wang, Yu Qing Wang, Ning Li, Fang Ying Lu, Xian Wen Sun, Li Yue Zhang, Jian Ping Zhou, Yong Jie Ding, Qing Yun LiBackgroundObstructive sleep apnoea (OSA) occurs frequently among individuals with obesity, which is attributed to upper airway muscle dysfunction. Muscle function is regulated by the dynamic balance of the nicotinamide adenine dinucleotide (NAD+) and its reduced form (NADH), which is controlled by the enzyme nicotinamide phosphoribosyltransferase (NAMPT). Elevated NAMPT levels have been found in individuals
-
Melatonin Ameliorates Age‐Related Sarcopenia via the Gut–Muscle Axis Mediated by Serum Lipopolysaccharide and Metabolites J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-04
Ling‐Shan Zhou, Yuan Yang, Li Mou, Xin Xia, Min Liu, Ling‐Jie Xu, Rong Liu, Jun‐Ping Liu, Hai‐Yan Zhang, Xiao‐Jun Ao, Chang‐Jiang Liu, Qian Xiao, Shi‐Xiong LiuBackgroundSarcopenia affects the quality of life and increases adverse outcomes in the elderly. However, as a potential safe and effective remedy to many age‐related disorders, little is known about the protective effect of melatonin against sarcopenia, especially the underlying mechanisms of pathophysiology related to the gut–muscle axis.MethodsThe young (4 months) and old‐aged (24 months) wild‐type
-
Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na‐MRI in Dysferlinopathy and Healthy Controls J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-03
Mary A. Neal, Carla F. Bolano‐Diaz, Mark Richardson, Jassi Michell‐Sodhi, Robert Muni‐Lofra, Meredith K. James, Kieren G. Hollingsworth, Heather Hilsden, Ian Wilson, Andrew M. Blamire, Volker Straub, Peter E. Thelwall, Jordi Diaz‐ManeraBackgroundDysferlin plays a key role in cell membrane repair; its absence or malfunction in patients with dysferlin‐deficient limb girdle muscular dystrophy leads to muscle fibre death. Muscle magnetic resonance (MR) imaging allows non‐invasive and repeatable measurements that can report on pathological changes observed in dysferlinopathy patients (DP). We aimed to demonstrate the feasibility of utilising
-
The Effect of Exercise on Spexin and Follistatin in Elderly Individuals J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-03
Elif Yıldırım Ayaz, Berna Dincer, Gülser Cinbaz, Esra Karacan, Reyhan Kaygusuz Benli, Emel Mete, Hilal Bilgiç, Banu MesciBackgroundIn adipose tissue–muscle crosstalk mechanisms, the interaction of adipokines and myokines is known to be critical for maintaining the body's metabolic balance in age‐related metabolic disorders. The aim of the study investigate the effects of 12 weeks of aerobic and resistance exercise training on spexin and follistatin and their relationship with each other.MethodsThis study was a multicentre
-
Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta‐Analysis J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-03
Chen Jiang, Qin Chen, Danping Yu, Qianqian Zhou, Cong Tang, Chenping QiaoBackgroundSarcopenia in gynaecologic oncology patients has garnered increasing attention, but its prevalence has not been comprehensively summarized. This study aims to integrate the prevalence of sarcopenia in this population through systematic evaluation and meta‐analysis, providing a reference for future clinical research.MethodsA computerized search of PubMed, Embase, The Cochrane Library, Web
-
Fat‐Free Mass: Friend or Foe to Metabolic Health? J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-02-03
Christopher J. Oliver, Mike Climstein, Nedeljka Rosic, Anja Bosy‐Westphal, Grant Tinsley, Stephen MyersBackgroundFat mass (FM) and fat‐free mass (FFM) are body composition estimates commonly reported in research studies and clinical settings. Recently, fat‐free mass indexed to height (fat‐free mass index; FFMI) has been shown to be positively associated with impaired insulin sensitivity or insulin resistance. Consequently, hypertrophic resistance training which can increase FFM was also questioned.
-
C‐Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta‐Analysis J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-30
Rida Fatima, Yonghoon Kim, Suhyeon Baek, Reema Priyanka Suram, Sun‐Joung Leigh An, Yonggeun HongBackgroundSarcopenia is a gradual decline in skeletal muscle mass and strength, which eventually leads to reduced physical performance. 50% of people aged 60–80 years suffer from sarcopenia. Considering the devastating outcomes and the importance of promoting healthy ageing, the diagnosis and prevention of sarcopenia is of utmost importance. Recently, C‐terminal agrin fragment (CAF) has been identified
-
Celecoxib Enhances Oxidative Muscle Fibre Formation and Improves Muscle Functions Through Prokr1 Activation in Mice J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-30
Jeong Hwan Park, Jongsoo Mok, Seoah Park, Dooho Kim, Min‐Su Kang, Tae Sub Park, Joonghoon ParkBackgroundMuscle diseases are serious challenges to human health. Prokineticin receptor 1 (PROKR1) has emerged as a potential target to improve muscle function through increasing oxidative muscle fibres, but there are no clinically applicable synthetic PROKR1 agonists.MethodsDrugs with biological properties of prokineticin 2 (PK2) were discovered through connectivity map (CMap) analysis. Their effects
-
Defective Cystic Fibrosis Transmembrane Conductance Regulator Accelerates Skeletal Muscle Aging by Impairing Autophagy/Myogenesis J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-30
Ziyi Chen, Jiankun Xu, Peijie Hu, Wanting Du, Junjiang Chen, Xiaotian Zhang, Wei Zhou, Jiayang Gao, Yuantao Zhang, Bingyang Dai, Guangshuai Nie, Jun Hu, Liangbin Zhou, Shunxiang Xu, Hisao Chang Chan, Wing‐hoi Cheung, Ye Chun Ruan, Ling QinBackgroundRegenerative capacity of skeletal muscles decreases with age. Deficiency in cystic fibrosis transmembrane conductance regulator (CFTR) is associated with skeletal muscle weakness as well as epithelial cell senescence. However, whether and how CFTR plays a role in skeletal muscle regeneration and aging were unclear.MethodsVastus lateralis biopsy samples from male and female human subjects
-
The Effect of Anti‐Activin Receptor Type IIA and Type IIB Antibody on Muscle, Bone and Blood in Healthy and Osteosarcopenic Mice J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-30
Frederik Duch Bromer, Andreas Lodberg, Marco Eijken, Christian Brix Folsted Andersen, Mathias Flensted Poulsen, Jesper Skovhus Thomsen, Annemarie BrüelBackgroundAnti‐Activin Receptor Type IIA and Type IIB antibody (αActRIIA/IIB ab) is a recently developed drug class that targets the activin receptor signalling pathway. Inhibition of receptor ligands (activins, myostatin, growth differentiation factor 11, etc.) can lead to skeletal muscle hypertrophy, bone formation, and increased haematopoiesis. Despite the αActRIIA/IIB ab, bimagrumab, having progressed
-
Characterization of SARS‐CoV‐2 Entry Genes in Skeletal Muscle and Impacts of In Vitro Versus In Vivo Infection J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-28
Salyan Bhattarai, Eva Kaufmann, Feng Liang, Yumin Zheng, Ekaterina Gusev, Qutayba Hamid, Jun Ding, Maziar Divangahi, Basil J. PetrofBackgroundCOVID‐19 has been associated with both respiratory (diaphragm) and non‐respiratory (limb) muscle atrophy. It is unclear if SARS‐CoV‐2 infection of skeletal muscle plays a role in these changes. This study sought to: 1) determine if cells comprising skeletal muscle tissue, particularly myofibres, express the molecular components required for SARS‐CoV‐2 infection; 2) assess the capacity for
-
PrPC Glycoprotein Is Indispensable for Maintenance of Skeletal Muscle Homeostasis During Aging J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-28
Wenduo Liu, Thi Thu Trang Kieu, Zilin Wang, Hyun‐Jaung Sim, Seohyeong Lee, Jeong‐Chae Lee, Yoonjung Park, Sang Hyun Kim, Sung‐Ho KookBackgroundThe cellular prion protein (PrPC), a glycoprotein encoded by the PRNP gene, is known to modulate muscle mass and exercise capacity. However, the role of PrPC in the maintenance and regeneration of skeletal muscle during ageing remains unclear.MethodsThis study investigated the change in PrPC expression during muscle formation using C2C12 cells and evaluated muscle function in Prnp wild‐type
-
Aptamer‐Conjugated Exosomes Ameliorate Diabetes‐Induced Muscle Atrophy by Enhancing SIRT1/FoxO1/3a‐Mediated Mitochondrial Function J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-28
Jia Song, Mengmeng Yang, Longqing Xia, Liming Wang, Kewei Wang, Yingyue Xiang, Jun Cheng, Jun Chen, Jidong Liu, Ruxing Zhao, Fuqiang Liu, Zheng Sun, Xinguo Hou, Nan Zang, Li ChenBackgroundMuscle atrophy is associated with Type 2 diabetes mellitus, which reduces the quality of life and lacks effective treatment strategies. Previously, it was determined that human umbilical cord mesenchymal stromal cell (hucMSC)–derived exosomes (EXOs) ameliorate diabetes‐induced muscle atrophy. However, the systemic application of EXOs is less selective for diseased tissues, which reduces their
-
A Natural Autophagy Activator Castanea crenata Flower Alleviates Skeletal Muscle Ageing J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-28
So‐Hyun Park, Pyeong Geun Choi, Hee‐Soo Kim, Eunyoung Lee, Da‐Hye Lee, Min Jung Kim, Daedong Kim, Hyo‐Deok Seo, Jeong‐Hoon Hahm, Tae‐Il Jeon, Yang‐Hoon Huh, Jiyun Ahn, Tae‐Youl Ha, Chang Hwa JungBackgroundSarcopenia, characterized by a gradual decline in skeletal muscle mass and function with age, significantly impacts both quality of life and mortality. Autophagy plays a crucial role in maintaining muscle health. There is growing interest in leveraging autophagy to mitigate muscle ageing effects. The impact of natural autophagy activators on skeletal muscle ageing remains elusive. This study
-
Testosterone Modulation of Muscle Transcriptomic Profile During Lifestyle Therapy in Older Men with Obesity and Hypogonadism J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-27
Viola Viola, Tagari Samanta, Maria Liza Duremdes Nava, Alessandra Celli, Reina Armamento‐Villareal, Ngoc Ho Lam Nguyen, Georgia Colleluori, Yoann Barnouin, Nicola Napoli, Clifford Qualls, Benny Abraham Kaipparettu, Dennis T. VillarealBackgroundTestosterone replacement therapy (TRT) added to lifestyle therapy can mitigate weight‐loss–induced reduction of muscle mass and bone mineral density (BMD) in older men with obesity and hypogonadism.ObjectiveTo investigate the molecular mechanisms underlying the attenuation of muscle and BMD loss in response to TRT during intensive lifestyle intervention in this high‐risk older population
-
Erector Spinae Muscle to Epicardial Visceral Fat Ratio on Chest CT Predicts the Severity of Coronavirus Disease 2019 J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-27
Takashi Shimada, Tomoki Maetani, Shotaro Chubachi, Naoya Tanabe, Takanori Asakura, Ho Namkoong, Hiromu Tanaka, Shuhei Azekawa, Shiro Otake, Kensuke Nakagawara, Takahiro Fukushima, Mayuko Watase, Yusuke Shiraishi, Hideki Terai, Mamoru Sasaki, Soichiro Ueda, Yukari Kato, Norihiro Harada, Shoji Suzuki, Shuichi Yoshida, Hiroki Tateno, Kaoruko Shimizu, Susumu Sato, Yoshitake Yamada, Masahiro Jinzaki, ToyohiroBackgroundChest computed tomography (CT) is a valuable tool for diagnosing and predicting the severity of coronavirus disease 2019 (COVID‐19) and assessing extrapulmonary organs. Reduced muscle mass and visceral fat accumulation are important features of a body composition phenotype in which obesity and muscle loss coexist, but their relationship with COVID‐19 outcomes remains unclear. In this study
-
Descriptive Epidemiology and Prognostic Significance of Diaphragm Thickness in the General Population: The Nagahama Study J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-25
Yasuharu Tabara, Takeshi Matsumoto, Kimihiko Murase, Takahisa Kawaguchi, Kazuya Setoh, Tomoko Wakamura, Toyohiro Hirai, Kazuo Chin, Fumihiko MatsudaBackgroundDiaphragm thickness is a potential marker of sarcopenia in addition to muscle mass and strength at extremities. We aimed to clarify the descriptive epidemiology and prognostic significance of diaphragm thickness in the general population.MethodsThe study participants were 3324 community residents (mean age: 61.4 ± 12.8 years) who participated in a longitudinal cohort study. Clinical parameters
-
Transcriptomic Profiling Reveals 17β‐Estradiol Treatment Represses Ubiquitin‐Proteasomal Mediators in Skeletal Muscle of Ovariectomized Mice J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-25
Georgios Kararigas, Mara C. Ebeling, Gengyun Le, Shaojuan Lai, Chunmei Cui, Qinghua Cui, Dawn A. LoweBackgroundWith a decline of 17β‐estradiol (E2) at menopause, E2 has been implicated in the accompanied loss of skeletal muscle mass and strength. We aimed at characterizing transcriptomic responses of skeletal muscle to E2 in female mice, testing the hypothesis that genes and pathways related to contraction and maintenance of mass are differentially expressed in ovariectomized mice with and without
-
Prevalence of Cachexia and Outcomes in Patients With Chronic Diseases: A National Database Analysis of 5 484 103 Hospitalisations J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-20
Mitja Lainscak, Tina Zupanic, Daniel Omersa, Ivan Erzen, Jerneja FarkasBackgroundCachexia is a frequent companion of chronic diseases and a well‐established predictor of poor patient performance and outcome. Since cachexia as a discharge diagnosis is not much investigated, we aimed to investigate prevalence of cachexia in hospitalised patients and their outcome.MethodsWe conducted a retrospective analysis of the National Hospital Health Care Statistics Database using
-
Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-17
Pauline Parent, Frédéric Pigneur, Marc Hilmi, Aurélien Carnot, Marie-Line Garcia Larnicol, Dewi Vernerey, Alain Luciani, Pascal Hammel, Julie Henriques, Cindy Neuzillet, Anthony TurpinAdvanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR-APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western patients receiving first-line chemotherapy. The study aimed to assess (1) the potential impact of computed tomography (CT)–quantified
-
Weight and Blood‐Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-16
Steven D. Tran, Noah J. Forrest, Vijeeth Guggilla, Geovanni M. Perottino, Jodi L. Johnson, Jeffrey Sosman, Ishan Roy, Theresa L. WalunasBackgroundCancer‐associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real‐world routinely collected clinical cachexia markers and disability‐free, hospitalization‐free and overall survival of cancer patients.MethodsA retrospective
-
The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-16
Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, Pratik Choudhary, Emma L. WatsonBackgroundObesity is a chronic disease associated with increased risk of multiple metabolic and mental health–related comorbidities. Recent advances in obesity pharmacotherapy, particularly with glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs), have the potential to transform obesity and type 2 diabetes mellitus (T2DM) care by promoting marked weight loss, improving glycaemic control and addressing
-
Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-15
Daria Neyroud, Andrew C. D'Lugos, Enrique J. Trevino, Chandler S. Callaway, Jacqueline Lamm, Orlando Laitano, Brittney Poole, Michael R. Deyhle, Justina Brantley, Lam Le, Andrew R. Judge, Sarah M. JudgeBackgroundCancer cachexia represents a debilitating muscle wasting condition that is highly prevalent in gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC). Cachexia is estimated to contribute to ~30% of cancer‐related deaths, with deterioration of respiratory muscles suspected to be a key contributor to cachexia‐associated morbidity and mortality. In recent studies, we identified
-
The Prognostic Value of Sarcopenia in Clinical Outcomes in Cervical Cancer: A Systematic Review and Meta‐Analysis J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-11
Fang Wang, Hongnan Zhen, Kang Yu, Pengju LiuBackgroundSarcopenia is a condition characterized by inadequate muscle and function decline and is often associated with ageing and cancer. It is established that sarcopenia and muscle loss occurred during treatment are associated with the clinical outcomes of patients with cancer. This systematic review and meta‐analysis aims to evaluate the association between sarcopenia at pretreatment and during
-
Ergogenic Benefits of β‐Hydroxy‐β‐Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta‐Analyses J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-11
Mohammad Vesal Bideshki, Mehrdad Behzadi, Mehrdad Jamali, Parsa Jamilian, Meysam Zarezadeh, Bahram Pourghassem GargariBackgroundβ‐Hydroxy‐β‐methyl butyrate (HMB) is a metabolite of the amino acid leucine, known for its ergogenic effects on body composition and strength. Despite these benefits, the magnitude of these effects remains unclear due to variability among studies. This umbrella review aims to synthesize meta‐analyses investigating the effects of HMB on body composition and muscle strength in adults.MethodsA
-
Large Variations in Phenylalanine Concentrations Associate Adverse Cardiac Remodelling in Adult Patients With Phenylketonuria—A Long‐Term CMR Study J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-11
Radu Tanacli, Patrick Doeblin, Alessandro Faragli, Jan‐Hendrik Hassel, Christian Stehning, Ursula Plöckinger, Athanasia Ziagaki, Sebastian KelleBackgroundDespite a phenylalanine (Phe) restrictive diet, most adult patients with ‘classical’ phenylketonuria (PKU) maintain life‐long Phe concentrations above the normal range and receive tyrosine (Tyr) and protein‐enriched diets to maintain acceptable concentrations and ensure normal development. While these interventions are highly successful in preventing adverse neuropsychiatric complications
-
Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-11
Chhanda Bose, Judit Megyesi, Oleg Karaduta, Sharda P. Singh, Sundararaman Swaminathan, Sudhir V. ShahBackgroundA decline in skeletal muscle mass and function known as skeletal muscle sarcopenia is an inevitable consequence of aging. Sarcopenia is a major cause of decreased muscle strength, physical frailty and increased muscle fatigability, contributing significantly to an increased risk of physical disability and functional dependence among the elderly. There remains a significant need for a novel
-
Adeno‐Associated Virus 8 and 9 Myofibre Type/Size Tropism Profiling Reveals Therapeutic Effect of Microdystrophin in Canines J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-10
Matthew J. Burke, Braiden M. Blatt, James A. Teixeira, Dennis O. Pérez‐López, Yongping Yue, Xiufang Pan, Chady H. Hakim, Gang Yao, Roland W. Herzog, Dongsheng DuanBackgroundAdeno‐associated virus (AAV) 8 and 9 are in clinical trials for treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD). Muscle consists of myofibres of different types and sizes. However, little is known about the fibre type and fibre size tropism of AAV in large mammals.MethodsWe evaluated fibre type‐ and size‐specific transduction properties of AAV8 and AAV9 in 17 dogs
-
Cut‐Off Points for Low Relative 30‐s Sit‐to‐Stand Power and Their Associations With Adverse Health Conditions J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-10
Mikel Garcia‐Aguirre, Ivan Baltasar‐Fernandez, Julian Alcazar, Jose Losa‐Reyna, Ana Alfaro‐Acha, Ignacio Ara, Leocadio Rodriguez‐Mañas, Luis M. Alegre, Francisco J. Garcia‐GarciaBackgroundDespite muscle power derived from the 5‐rep sit‐to‐stand (STS) test having been demonstrated to be a valuable biomarker in older individuals, there is limited information regarding muscle power derived from the 30‐s STS test, a widely used test in the clinical setting. This study aimed (i) to compare relative 30‐s STS power values between older men and women, (ii) to identify cut‐off points
-
Reference Values of Handgrip and Lower Extremity Strength for Vietnamese Men and Women: The Vietnam Osteoporosis Study J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2025-01-10
Kiet T. Do, Duy K. Hoang, Quan N. Luong, Huy G. Nguyen, An T. Do, Lan T. Ho‐Pham, Tuan V. NguyenBackgroundFalls and sarcopenia are significant public health issues in Vietnam. Despite muscle strength being a critical predictor for these conditions, reference data on muscle strength within the Vietnamese population are lacking.PurposeTo establish the reference ranges for muscle strength among Vietnamese individuals.MethodsThe study involved 4096 individuals, including 1419 men and 2677 women aged
-
Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-27
Carmen Scheibenbogen, Klaus J. WirthBackgroundRecent studies provide strong evidence for a key role of skeletal muscle pathophysiology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In a 2021 review article on the pathophysiology of ME/CFS, we postulated that hypoperfusion and ischemia can result in excessive sodium and calcium overload in skeletal muscles of ME/CFS patients to cause mitochondrial damage. Since then
-
Comparison Between Single‐ and Multi‐slice Computed Tomography Body Composition Analysis in Patients With Oesophagogastric Cancer J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Leo R. Brown, Maria Soupashi, Michael S. Yule, Danielle R. Clyde, Ellen Gardner, Charlotte Smith, Ahmed Dhaif, Barry J. A. Laird, Stephen J. Wigmore, Richard J. E. SkipworthBackgroundSingle‐slice computed tomography (CT) body composition has been studied extensively for prognostication in patients with cancer. New software packages can also provide multi‐slice volumetric measurements, but the clinical utility of these remains under explored. This study aimed to evaluate the agreement between single‐ and multi‐slice body composition analyses in patients with oesophagogastric
-
Correction to ‘Hepatic signal transducer and activator of transcription‐3 signalling drives early‐stage pancreatic cancer cachexia via suppressed ketogenesis’ J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Arneson-Wissink P. C., Mendez H., Pelz K., Dickie J., Bartlett A. Q., Worley B. L., et al (2024) Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis, Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13466. In our attribution of funding, we mistakenly omitted the following: PCAW was supported
-
Succinate Regulates Exercise‐Induced Muscle Remodelling by Boosting Satellite Cell Differentiation Through Succinate Receptor 1 J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Yifan Shi, Da Zhou, Haoyang Wang, Longchang Huang, Xuejin Gao, Gulisudumu Maitiabula, Li Zhang, Xinying WangBackgroundSkeletal muscle remodelling can cause clinically important changes in muscle phenotypes. Satellite cells (SCs) myogenic potential underlies the maintenance of muscle plasticity. Accumulating evidence shows the importance of succinate in muscle metabolism and function. However, whether succinate can affect SC function and subsequently coordinate muscle remodelling to exercise remains unexplored
-
Intrinsic Muscle Stem Cell Dysfunction Contributes to Impaired Regeneration in the mdx Mouse J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Marie E. Esper, Caroline E. Brun, Alexander Y. T. Lin, Peter Feige, Marie J. Catenacci, Marie‐Claude Sincennes, Morten Ritso, Michael A. RudnickiBackgroundDuchenne muscular dystrophy (DMD) is a devastating disease characterized by progressive muscle wasting that leads to diminished lifespan. In addition to the inherent weakness of dystrophin‐deficient muscle, the dysfunction of resident muscle stem cells (MuSC) significantly contributes to disease progression.MethodsUsing the mdx mouse model of DMD, we performed an in‐depth characterization
-
Comment on ‘Artificial Neural Network Inference Analysis Identified Novel Genes and Gene Interactions Associated With Skeletal Muscle Aging’ by Tarum et al. J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Jing‐Lu Zheng, Xi‐Yang Chen, Yi‐Kai Li, Hong‐Wen LiuWe read with great interest the recent article by Tarum et al. [1], titled ‘Artificial Neural Network Inference Analysis Identified Novel Genes and Gene Interactions Associated With Skeletal Muscle Aging’. This study introduces an innovative application of artificial neural network inference (ANNi) to elucidate complex gene networks implicated in skeletal muscle ageing. The findings provide significant
-
Distinct Gut Microbiota Profiles in Normal Weight Obesity and Their Association With Cardiometabolic Diseases: Results From Two Independent Cohort Studies J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Wenjie Wang, Feijie Wang, Yihan Li, Yuwei Shi, Xiaoyan Wang, Xinyu Chen, Weifang Zheng, Julianna C. Hsing, Ying Lu, Yi‐Shuan Wu, Ann W. Hsing, Juntao Kan, Wei He, Shankuan ZhuBackgroundNormal weight obesity (NWO) is characterized by excess body fat in individuals with normal body mass index (BMI). This study aimed to investigate gut microbiota alterations in NWO and their potential associations with cardiometabolic diseases (CMD) risk in two independent cohorts.MethodsOur NWO‐CMD mortality analysis included 168 099 adults with normal BMI from two large open‐access databases
-
NLRP3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body Myositis J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Elie Naddaf, Thi Kim Oanh Nguyen, Jens O. Watzlawik, Huanyao Gao, Xu Hou, Fabienne C. Fiesel, Jay Mandrekar, Eileen Kokesh, William S. Harmsen, Ian R. Lanza, Wolfdieter Springer, Eugenia TrushinaBackgroundInclusion body myositis (IBM) is the most prevalent muscle disease in adults for which no current treatment exists. The pathogenesis of IBM remains poorly defined. In this study, we aimed to explore the interplay between inflammation and mitochondrial dysfunction in IBM.MethodsThe study population consisted of 38 IBM patients and 22 age‐ and sex‐matched controls without a myopathy. Mean age
-
Anorexia of Ageing, an Underappreciated Perioperative Concern? J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-26
Brandon Stretton, Joshua Kovoor, Aashray Gupta, Stephen BacchiIntroduction Between early 2000 and 2050, the number of people aged > 60 is expected to double, approaching 22% in developed regions [1]. As half of the population aged over 65 will require surgery at some point, reducing operative burden, particularly in the elderly, is a major public health concern [2]. One such age-related change that was first described in 1994, which is yet to receive the recognition
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-23
No abstract is available for this article.
-
Comment on ‘Association of Computed Tomography‐Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta‐Analysis’ by Van Helsdingen et al. J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-23
Rachana Mehta, Ashok Kumar Balaraman, Muhammed Shabil, Sanjit SahWe read with great interest the article titled ‘Association of computed tomography-derived body composition and complications after colorectal cancer surgery A systematic review and meta-analysis’ and commend the authors for their rigorous and insightful systematic review and meta-analysis on body composition measurements using computed tomography (CT) scans as predictors of complications following
-
Comment on ‘Association Between Dynapenic Obesity and Risk of Cardiovascular Disease: The Hisayama Study’ by Setoyama et al. J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-23
Chang Liu, Fan Zhang, Min CaoWe have read with interest the article by Setoyama Y et al. [1] titled ‘Association of dynapenic obesity with cardiovascular disease: The Hisayama Study.’ While this study provides valuable insights into the relationship between dynapenic obesity and cardiovascular disease risk, we would like to highlight three points that warrant further discussion. First, the authors introduce the concept of ‘dynapenic
-
CT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-23
Smith Giri, Christian Harmon, Daniel Hess, Elizabeth M. Cespedes Feliciano, Ijeamaka Anyene Fumagalli, Bette Caan, Leon Lenchik, Karteek Popuri, Vincent Chow, Mirza Faisal Beg, Smita Bhatia, Grant R. WilliamsOlder adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico-demographic characteristics inadequately explain this increased risk limiting accurate prognostication. Prior studies have suggested that altered body composition and frailty are independently associated with worse survival among older adults with cancer; however, their combined
-
Chaperone Proteins: The Rising Players in Muscle Atrophy J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-20
Davide Acquarone, Alessandro Bertero, Mara Brancaccio, Matteo SorgeDespite significant progress in understanding the molecular aetiology of muscle atrophy, there is still a great need for new targets and drugs capable of counteracting muscle wasting. The role of an impaired proteostasis as the underlying causal mechanism of muscle atrophy is a well-established concept. From the earliest work on muscle atrophy and the identification of the first atrogenes, the hyper-activation
-
Acute Sarcopenia: Systematic Review and Meta-Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-17
Luke Aldrich, Theocharis Ispoglou, Konstantinos Prokopidis, Jasem Alqallaf, Oliver Wilson, Antonis Stavropoulos-KalinoglouAcute sarcopenia is sarcopenia lasting less than 6 months, typically following acute illness or injury. It may impact patient recovery and quality of life, advancing to chronic sarcopenia. However, its development and assessment remain poorly understood, particularly during hospitalisation. This systematic review aimed to elucidate the incidence of acute sarcopenia and examine changes in muscle parameters
-
Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-17
Sanghoon Bae, Van-Hieu Mai, Seyoung Mun, Dalong Dong, Kyudong Han, Sunghyouk Park, Jung Keun HyunMuscle atrophy, including glucocorticoid-induced muscle wasting from treatments such as dexamethasone (DEX), results in significant reductions in muscle mass, strength and function. This study investigates the potential of lonafarnib, a farnesyltransferase inhibitor, to counteract DEX-induced muscle atrophy by targeting key signalling pathways.
-
Muscle Mass Index Decline as a Predictor of Lung Function Reduction in the General Population J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-17
Joon Young Choi, Chin Kook Rhee, Sang Hyuk Kim, Yong Suk JoThis study explores the link between muscle mass decline and lung function deterioration, which can worsen respiratory health by reducing exercise capacity and quality of life. The relationship between muscle mass index (MMI) changes and lung function in the general population remains unclear, especially as muscle mass fluctuates with aging. We aimed to clarify this dynamic relationship by examining
-
Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-17
Hyunwook Kim, Seungjin Baek, Sookyeong Han, Gun Min Kim, Joohyuk Sohn, Yumie Rhee, Namki Hong, Min Hwan KimRecent evidence indicates that a dysregulated host metabolism influences treatment outcomes in patients with breast cancer. We investigated the association of computed tomography (CT)-derived body composition indices with therapeutic responses in patients with hormone receptor-positive, HER2-negative advanced breast cancer (ABC) on endocrine plus CDK4/6 inhibitor (CDK4/6i) treatment.
-
Risk of Sarcopenia Following Long-Term Statin Use in Community-Dwelling Middle-Aged and Older Adults in Japan J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-16
Shih-Tsung Huang, Rei Otsuka, Yukiko Nishita, Lin-Chieh Meng, Fei-Yuan Hsiao, Hiroshi Shimokata, Liang-Kung Chen, Hidenori AraiInconsistent results have been reported concerning the association between statin administration and muscle health, specifically its potential to increase the risk of sarcopenia. Given the widespread long-term use of statins among the elderly population, the exploration of this association remains a crucial yet insufficiently examined matter. This study aimed to assess the association between the prolonged
-
Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-12
Frank Misselwitz, Dennis Henderson, Somasekhara R. Menakuru, Elaine Morten, Chris Roe, Gareth Whitaker, Stefan Wohlfeil, John McDermottS-pindolol has metabolic effects of potential benefit in cancer cachexia: reduced catabolism through nonselective β-blockade; increased anabolism through partial β2 receptor agonism; and increased appetite and reduced fatigue through central 5-hydroxytryptamine/serotonin receptor activity. A Phase 2a clinical trial demonstrated that S-pindolol can reverse weight loss and improve fat-free mass in patients
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 9.4) Pub Date : 2024-12-12
No abstract is available for this article.